Co-Stimulatory Receptors in Cancers and Their Implications for Cancer Immunotherapy
Immune Network
;
: e3-2020.
Article
in English
| WPRIM
| ID: wpr-890859
ABSTRACT
Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic agents, are now approved by the Food and Drug Administration for treatment of various types of cancer. However, the therapeutic efficacy of ICIs varies among patients and cancer types. Moreover, most patients do not develop durable antitumor responses after ICI therapy due to an ephemeral reversal of T-cell dysfunction. As co-stimulatory receptors play key roles in regulating the effector functions of T cells, activating co-stimulatory pathways may improve checkpoint inhibition efficacy, and lead to durable antitumor responses. Here, we review recent advances in our understating of co-stimulatory receptors in cancers, providing the necessary groundwork for the rational design of cancer immunotherapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
English
Journal:
Immune Network
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS